Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Leukemia

• Publication date

  2012-01-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2011.381PMID 22289923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Colony Stimulating Factor

  2020cited by this paper
• The role of osteocyte apoptosis in cancer chemotherapy‐induced bone loss

  2012cited by this paper
• Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression.

  2012cited by this paper
• Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy

  2012cited by this paper
• Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro

  2011cited by this paper
• Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

  2011cited by this paper
• Sclerostin is overexpressed by plasma cells from multiple myeloma patients

  2011cited by this paper
• Therapeutic options in the management of myeloma bone disease.

  2010cited by this paper
• Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression

  2010cited by this paper
• The Amazing Osteocyte

  2010cited by this paper
• Osteocyte apoptosis and control of bone resorption following ovariectomy in mice.

  2010cited by this paper
• Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone

  2010cited by this paper
• Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model

  2009cited by this paper
• Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited.

  2009cited by this paper
• The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

  2009cited by this paper
• Pro‐Inflammatory Cytokines TNF‐Related Weak Inducer of Apoptosis (TWEAK) and TNFα Induce the Mitogen‐Activated Protein Kinase (MAPK)‐Dependent Expression of Sclerostin in Human Osteoblasts

  2009cited by this paper
• Pathogenesis of myeloma bone disease

  2009cited by this paper
• Human Primary Osteocyte Differentiation in a 3D Culture System

  2009cited by this paper
• Apoptotic Bodies Convey Activity Capable of Initiating Osteoclastogenesis and Localized Bone Destruction

  2008cited by this paper
• Metastases and multiple myeloma generate distinct transcriptional footprints in osteocytes in vivo

  2008cited by this paper
• Matrix metalloproteinase-1 is a crucial bone metastasis factor in a human breast cancer-derived highly invasive cell line.

  2008cited by this paper
• Differentiation of osteoblasts and osteocytes from mesenchymal stem cells.

  2008cited by this paper
• HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

  2007cited by this paper
• Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.

  2007cited by this paper
• Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

  2006cited by this paper
• IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

  2005cited by this paper
• Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption.

  2005cited by this paper
• The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.

  2004cited by this paper
• New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

  2004cited by this paper
• Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

  2004cited by this paper
• Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.

  2004cited by this paper
• MIP-1 alpha and myeloma bone disease.

  2004cited by this paper
• Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.

  2004cited by this paper
• Breast cancer cells induce osteoclast formation by stimulating host IL‐11 production and downregulating granulocyte/macrophage colony‐stimulating factor

  2004cited by this paper
• Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.

  2004cited by this paper
• CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4.

  2003cited by this paper
• Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model.

  2003cited by this paper
• Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

  2003cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.

  2002cited by this paper
• MLO‐Y4 Osteocyte‐Like Cells Support Osteoclast Formation and Activation

  2002cited by this paper
• Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.

  2002cited by this paper
• Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

  2002cited by this paper
• Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.

  2001cited by this paper
• Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases.

  2001cited by this paper
• Osteocyte-osteoclast morphological relationships and the putative role of osteocytes in bone remodeling.

  2001cited by this paper
• Osteocyte function, osteocyte death and bone fracture resistance.

  2000cited by this paper
• Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.

  2000cited by this paper
• Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease

  1999cited by this paper
• Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.

  1999cited by this paper
• Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.

  1999cited by this paper
• Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis

  1998cited by this paper
• Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.

  1998cited by this paper
• Recurrent bacteremia caused by Rhodococcus equi in a non-neutropenic patient with acute myeloid leukemia in complete remission.

  1998cited by this paper
• The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone.

  1997cited by this paper
• Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells.

  1997cited by this paper
• Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies.

  1996cited by this paper
• The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures

  1996cited by this paper
• Establishment and hormonal regulation of a conditionally transformed preosteocytic cell line from adult human bone.

  1996cited by this paper
• Interleukin-11: a new cytokine critical for osteoclast development.

  1994cited by this paper

• Models of myeloma bone disease: In vivo and in vitro approaches.

  2026cites this paper
• Engineered bone matrix models for understanding breast cancer skeletal metastasis

  2026cites this paper
• Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives

  2025cites this paper
• Plasma level of osteopontin in multiple myeloma: Its correlation with international staging system and clinical and laboratory findings

  2025cites this paper
• Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies.

  2025cites this paper
• Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice

  2025cites this paper
• Fractures incidence and its association on mortality in multiple myeloma patients: a nationwide cohort study (CAREMM-2105 study)

  2025cites this paper
• Skeletal health in the precursor stages of multiple myeloma: fracture risk and bone phenotypes in monoclonal gammopathy of undetermined significance and smouldering myeloma.

  2025cites this paper
• Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Dynamics as a Complementary Marker of Treatment Response in Newly Diagnosed Multiple Myeloma: A Prospective Analysis

  2025cites this paper
• Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition

  2025cites this paper
• Multiple myeloma presenting as a giant osteolytic skull mass: Surgical challenges and pitfalls – A case report

  2025cites this paper
• Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study

  2025cites this paper
• Adipocyte–Tumor Interactions in the Bone Marrow Niche: Implications for Metastasis and Therapy

  2025cites this paper
• Melanoma bone metastasis-induced osteocyte ferroptosis via the HIF1α-HMOX1 axis

  2025cites this paper
• A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma

  2024cites this paper
• Aberrant NSUN2-mediated m5C modification of exosomal LncRNA MALAT1 induced RANKL-mediated bone destruction in multiple myeloma

  2024cites this paper
• Single-cell Transcriptomic Analysis Identifies Senescent Osteocytes that Trigger Bone Destruction in Breast Cancer Metastasis.

  2024cites this paper
• Evidence for peri-lacunar remodeling and altered osteocyte lacuno-canalicular network in mouse models of myeloma-induced bone disease

  2024influential citation
• Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis

  2024cites this paper
• Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier

  2024cites this paper
• Novel insights into osteocyte and inter-organ/tissue crosstalk.

  2024cites this paper
• Role of the osteocyte in bone metastasis – The importance of networking

  2024cites this paper
• Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy

  2024cites this paper
• Regulation of the Osteocyte Secretome with Aging and Disease

  2023cites this paper
• Osteocytes: New Kids on the Block for Cancer in Bone Therapy

  2023cites this paper
• Bone-homing metastatic breast cancer cells impair osteocytes’ mechanoresponse in a 3D loading model

  2023cites this paper
• Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma.

  2023cites this paper
• Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents

  2023cites this paper
• Oscillating Fluid Flow Activated Osteocyte Lysate‐Based Hydrogel for Regulating Osteoblast/Osteoclast Homeostasis to Enhance Bone Repair

  2023cites this paper
• Does Waldenstrom’s macroglobulinemia also cause bone destruction? A rare case report

  2022cites this paper
• Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction

  2022cites this paper
• Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment

  2022cites this paper
• Pathogenesis and Treatment of Myeloma-Related Bone Disease

  2022cites this paper
• Osteocytes and bone tumor niche

  2022cites this paper
• Recent therapeutic approaches in myeloma

  2022cites this paper
• Multi-Tissue Analysis Using Synchrotron Radiation Micro-CT Images

  2022cites this paper
• Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance

  2022cites this paper
• Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine—Are We There Yet?

  2022cites this paper
• Pathophysiology and therapeutic advances in myeloma bone disease

  2022cites this paper
• Osteocyte CIITA aggravates osteolytic bone lesions in myeloma

  2022cites this paper
• Osteocytes and Cancer

  2021cites this paper
• Exosomal microRNA panels as biomarkers for hematological malignancies.

  2021cites this paper
• Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease

  2021cites this paper
• The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma

  2021cites this paper
• The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes

  2021cites this paper
• Therapy of Myeloma Bone Disease

  2021cites this paper
• Stem cell niches in bone and their roles in cancer metastasis

  2021cites this paper
• Myeloma Bone Disease: A Comprehensive Review

  2021cites this paper
• Non-bone metastatic cancers promote osteocyte-induced bone destruction.

  2021cites this paper
• The Osteocyte as a Signaling Cell.

  2021cites this paper
• Myeloma–Bone Interaction: A Vicious Cycle via TAK1–PIM2 Signaling

  2021cites this paper
• Impact of MGUS and myeloma on skeletal health

  2021cites this paper
• Microcracks on the Rat Root Surface Induced by Orthodontic Force, Crack Extension Simulation, and Proteomics Study

  2021cites this paper
• Aberrant ENPP2 expression promotes tumor progression in multiple myeloma

  2021cites this paper
• Evolving cancer–niche interactions and therapeutic targets during bone metastasis

  2021cites this paper
• Mechanobiology of Bone Metastatic Cancer

  2021cites this paper
• Osteocyte Mechanobiology in Aging and Disease

  2020cites this paper
• Therapeutic targets in myeloma bone disease

  2020cites this paper
• The Roles of Bone Marrow-Resident Cells as a Microenvironment for Bone Metastasis.

  2020cites this paper
• Tumor Microenvironments in Organs: From the Brain to the Skin – Part A

  2020cites this paper
• Pathological Crosstalk between Metastatic Breast Cancer Cells and the Bone Microenvironment

  2020cites this paper
• Omurilik Basısı Nedeniyle Dekompresyon Uygulanan Multipl Miyelom Olgularının Değerlendirilmesi

  2020cites this paper
• Basic Aspects of Osteocyte Function

  2020cites this paper
• Myeloma Bone Disease

  2020cites this paper
• Bone, a Secondary Growth Site of Breast and Prostate Carcinomas: Role of Osteocytes

  2020cites this paper
• Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2

  2020cites this paper
• Osteocytes and Bone Metastasis

  2020cites this paper
• Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23

  2020cites this paper
• The impact of the bone marrow microenvironment on multiple myeloma (Review).

  2019cites this paper
• Myeloma bone disease: from biology findings to treatment approaches.

  2019cites this paper
• Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease.

  2019cites this paper
• Why do myeloma patients have bone disease? A historical perspective.

  2019cites this paper
• The Emerging Role of Osteocytes in Cancer in Bone

  2019influential citation
• Bone Mechanics in Cancer

  2019cites this paper
• Multiple Roles of Osteocytes in Bone-Associated Cancers

  2019cites this paper
• Understanding the Bone in Cancer Metastasis

  2018cites this paper
• Mechanically-Loaded Breast Cancer Cells Modify Osteocyte Mechanosensitivity by Secreting Factors That Increase Osteocyte Dendrite Formation and Downstream Resorption

  2018cites this paper
• Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy

  2018influential citation
• Heme oxygenase‐1 attenuates the inhibitory effect of bortezomib against the APRIL‐NF‐κB‐CCL3 signaling pathways in multiple myeloma cells: Corelated with bortezomib tolerance in multiple myeloma

  2018cites this paper
• Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes

  2018cites this paper
• Myeloma Bone Disease and Other Hematological Malignancies

  2018cites this paper
• The Proteasome and Myeloma-Associated Bone Disease

  2018cites this paper
• Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

  2018cites this paper
• Engineering 3D approaches to model the dynamic microenvironments of cancer bone metastasis

  2018cites this paper
• Multiple Myeloma and Bone: The Fatal Interaction.

  2018cites this paper
• Pathogenesis of bone disease in multiple myeloma: from bench to bedside

  2018cites this paper
• Molecular mechanisms, current management and next generation therapy in myeloma bone disease

  2018cites this paper
• Mechanisms of Osteolytic and Osteoblastic Skeletal Lesions

  2018cites this paper
• Osteoclasts Control Lipid Secretion to Regulate Breast Cancer Bone Metastasis.

  2017cites this paper
• Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials

  2017cites this paper
• Myeloma bone disease: pathogenesis and treatment.

  2017cites this paper
• Genetic Deletion of Sost or Pharmacological Inhibition of Sclerostin Prevent Multiple Myeloma-induced Bone Disease without Affecting Tumor Growth

  2017influential citation
• Multiple myeloma bone disease: from mechanisms to next generation therapy

  2017cites this paper
• L’os du myélome multiple : physiopathologie

  2017cites this paper
• Osteocytes and Their Messengers as Targets for the Treatment of Multiple Myeloma

  2017influential citation
• Ex vivo construction of human primary 3D-networked osteocytes.

  2017cites this paper
• Mechanisms of Altered Bone Remodeling in Multiple Myeloma

  2017cites this paper
• Characterisation of pathogenic pathways within the bone microenvironment of Gaucher disease which contribute to bone pathology and haematological malignancy

  2017cites this paper
• New agents in the Treatment of Myeloma Bone Disease

  2017cites this paper
• Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease

  2017cites this paper